全文获取类型
收费全文 | 80549篇 |
免费 | 7638篇 |
国内免费 | 5339篇 |
专业分类
耳鼻咽喉 | 574篇 |
儿科学 | 986篇 |
妇产科学 | 1234篇 |
基础医学 | 9750篇 |
口腔科学 | 1578篇 |
临床医学 | 10263篇 |
内科学 | 12650篇 |
皮肤病学 | 836篇 |
神经病学 | 4398篇 |
特种医学 | 2816篇 |
外国民族医学 | 32篇 |
外科学 | 7762篇 |
综合类 | 12992篇 |
现状与发展 | 14篇 |
一般理论 | 12篇 |
预防医学 | 5509篇 |
眼科学 | 2117篇 |
药学 | 8727篇 |
80篇 | |
中国医学 | 4327篇 |
肿瘤学 | 6869篇 |
出版年
2024年 | 329篇 |
2023年 | 1290篇 |
2022年 | 3193篇 |
2021年 | 4049篇 |
2020年 | 3082篇 |
2019年 | 2624篇 |
2018年 | 2809篇 |
2017年 | 2515篇 |
2016年 | 2364篇 |
2015年 | 3599篇 |
2014年 | 4365篇 |
2013年 | 4103篇 |
2012年 | 6184篇 |
2011年 | 6515篇 |
2010年 | 4190篇 |
2009年 | 3299篇 |
2008年 | 4453篇 |
2007年 | 4314篇 |
2006年 | 3884篇 |
2005年 | 3823篇 |
2004年 | 2754篇 |
2003年 | 2497篇 |
2002年 | 2240篇 |
2001年 | 1826篇 |
2000年 | 1915篇 |
1999年 | 2001篇 |
1998年 | 1276篇 |
1997年 | 1261篇 |
1996年 | 990篇 |
1995年 | 954篇 |
1994年 | 782篇 |
1993年 | 485篇 |
1992年 | 563篇 |
1991年 | 518篇 |
1990年 | 438篇 |
1989年 | 391篇 |
1988年 | 309篇 |
1987年 | 306篇 |
1986年 | 235篇 |
1985年 | 186篇 |
1984年 | 123篇 |
1983年 | 84篇 |
1982年 | 62篇 |
1981年 | 47篇 |
1980年 | 33篇 |
1979年 | 44篇 |
1978年 | 18篇 |
1974年 | 17篇 |
1973年 | 17篇 |
1966年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
胃底贲门癌根治性切除与扩大根治性切除的疗效对比 总被引:12,自引:0,他引:12
目的 探讨胃底贲门癌根治手术的最佳范围。方法 对418例胃底贲门癌患者施行根治性手术,其中扩大根治性切除192例(扩大组),Ⅰ期11例,Ⅱ期40例,Ⅲ期121例,Ⅳ期20例,根治性切除226例,Ⅰ期19例,Ⅱ期53例,Ⅲ期131,Ⅳ期23例。对2且2术后5、10年生存率进行对照分析。结果 2种术式的5、10年生存率;Ⅰ、Ⅱ期患者相似,差异无显著性意义;而Ⅲ期患者扩大组5、10年生存率较根治组分别提 相似文献
992.
脾切除对大鼠血浆及肝肺组织中内毒素廓清的影响 总被引:1,自引:0,他引:1
目的 观察脾切除对血浆中内毒素清除的影响及内毒素在主要脏器的分布特征,探索脾切除后上反应与组织损害的发生机制。方法 雄性Wistar大鼠112只,随机分为有脾组(n=56,行大网膜切除术,保留脾脏)、脾切除组(n=56,行脾切除术)。术后1周静脉注射内毒素0.1mg/kg,分别于注射前、注射后10min、0.5、1.5、4、12、24h活杀动物,测定血浆和肝、肺组织内毒素水平,同时检测肝、肺脏器功 相似文献
993.
Jun Lu Brian D Palmer Phillip Kestell Peter Browett Bruce C Baguley George Muller Lai-Ming Ching 《Clinical cancer research》2003,9(5):1680-1688
PURPOSE:This research examines the profile of metabolites of thalidomide that are formed in refractory multiple myeloma patients undergoing thalidomide therapy in comparison with those that are detected in healthy mice. EXPERIMENTAL DESIGN: Urine or plasma samples from patients during thalidomide therapy (100-400 mg daily), or from mice treated i.p. (100 mg/kg) or p.o. with thalidomide (50 mg/kg) were analyzed using liquid chromatography-mass spectrometry. Metabolites in each of the peaks observed in the UV- and mass spectrometry-detected high-performance liquid chromatography traces were identified by comparison of retention times and spectra with those of authentic standards. RESULTS: Plasma and urine samples from mice 4 h after treatment with thalidomide contained eight major metabolites formed by hydroxylation and/or hydrolysis of thalidomide. In contrast, urine samples from seven multiple myeloma patients at steady state levels of thalidomide therapy showed the presence of only three hydrolysis breakdown products and no hydroxylated metabolites. CONCLUSIONS: Our results show that thalidomide metabolite profiles in multiple myeloma patients differ considerably from those in mice. The lack of measurable hydroxylated metabolites in urine and in 1 case plasma of these patients suggests that such metabolites are not responsible for the therapeutic effects of thalidomide in multiple myeloma. We suggest that thalidomide may act directly, down-regulating growth factors essential for multiple myeloma growth. 相似文献
994.
1038例原发性肝癌的外科治疗 总被引:16,自引:0,他引:16
目的 探讨提高我国肝癌手术治疗的安全性及疗效的措施。方法 分析 1990年 1月至 1998年 12月经手术治疗的原发性肝癌 10 38例 ,其中前期组 (1990年 1月至 1996年 12月 ) 731例 ,肿瘤切除手术 312例 (42 7% ) ,非切除手术 419例 ;后期组 (1997年 1个月至 1998年 12月 ) 30 7例 ,肿瘤切除手术 2 17例 (70 7% ) ,非切除手术 90例。 结果 小肝癌 (直径≤ 5cm)前期组占 7 1% ,后期组 19 9% ;前期组肝癌切除术后 1个月内病死率 2 2 % ,并发症发生率 2 3 7% ,术后 1、3、5年生存率分别为 73 1%、5 4 2 %及 34 0 % ,后期组肝癌切除术后 1个月病死率 0 7% ,并发症发生率 2 2 1% ,术后1、3、5年生存率为 91 1%、6 3 8%及 40 2 %。 结论 (1)对高危患者定期随访有助于早期发现小肝癌 ;(2 )小肝癌比例的上升 ,围手术期处理的进步及手术技术的改进有助于提高肝癌切除率及长期生存率 ;(3)治疗模式的规范化及新技术 ,如半肝血流阻断、体外静脉转流、门静脉癌栓摘取、原位肝移植等有助于提高手术安全性及疗效。 相似文献
995.
中药复方化学与创新药物研究 总被引:2,自引:0,他引:2
中药复方化学与创新药物研究是中药现代化研究中的关键课题,本文简要回顾了中药复方化学研究的概况,论述了中药复方化学研究的思路和方法学,结合研究实践,阐明以中药复方化学研究所发掘出的中药复方有效部位(群)或有效成分(群)为基础,研制创新药物是实现中药现代化与国际化的有效途径。 相似文献
996.
Objective To retrospectively analyze the therapeutic results of patients with initially di-agnosed metastatic nasopharyngeal carcinoma (NPC). Methods From January 1995 to December 1998, 46 NPC patients with distant metastases were treated in Fujian provincial cancer hospital. Among these pa-tients, 43 were single site metastasis and 3 were multiple sites metastases;The site of metastasis were 19 pa-tients in the liver, 11 in the bone, 7 in the lung, 1 in the brain, 6 in mediastinal nodes and 6 in axillary lymph nodes. All patients received standard radiotherapy to the primary site and cervical node region with a median dose of 72 Gy. Forty-one patients (89%) received 1-5 cycles chemotherapy (cisplatin and 5-flu-orouracil), and 23 (50%) received palliative irradiation to the metastatic site. Results The median surviv-al time was 20 months. The 1-, 2-, 3-year and 5-year overall survival rates were 66%, 47%, 30% and 19%, respectively. Irradiation to the metastatic sites and KPS were the significant prognostic factors. Pa-tients with palliative irradiation to the metastatic site had longer survival than those without (39 months vs. 13 months, X2=8.63, P=0.012). Patients with good performance status (KPS≥80) had better outcomes thanthose with poor performance status (26 months vs. 12 months, X2= 3.95, P=0.035) . Conclusions Active therapy may prolong the survival of patients with initially diagnosed metastatic NPC, especially for those who have good performance status. Under systematic chemotherapy, radiotherapy to the primary site and supportive care, the palliative irradiation to the metastatic site may also yield a good result. 相似文献
997.
998.
Z Zhu K Hattori H Zhang X Jimenez D L Ludwig S Dias P Kussie H Koo H J Kim D Lu M Liu R Tejada M Friedrich P Bohlen L Witte S Rafii 《Leukemia》2003,17(3):604-611
Vascular endothelial growth factor (VEGF) and its receptors (VEGFR) have been implicated in promoting solid tumor growth and metastasis via stimulating tumor-associated angiogenesis. We recently showed that certain 'liquid' tumors such as leukemia not only produce VEGF, but also express functional VEGFR, resulting in an autocrine loop for tumor growth and propagation. A chimeric anti-VEGFR2 (or kinase insert domain-containing receptor, KDR) antibody, IMC-1C11, was shown to be able to inhibit VEGF-induced proliferation of human leukemia cells in vitro, and to prolong survival of nonobese diabetic-severe combined immune deficient (NOD-SCID) mice inoculated with human leukemia cells. Here we produced two fully human anti-KDR antibodies (IgG1), IMC-2C6 and IMC-1121, from Fab fragments originally isolated from a large antibody phage display library. These antibodies bind specifically to KDR with high affinities: 50 and 200 pM for IMC-1121 and IMC-2C6, respectively, as compared to 270 pM for IMC-1C11. Like IMC-1C11, both human antibodies block VEGF/KDR interaction with an IC(50) of approximately 1 nM, but IMC-1121 is a more potent inhibitor to VEGF-stimulated proliferation of human endothelial cells. These anti-KDR antibodies strongly inhibited VEGF-induced migration of human leukemia cells in vitro, and when administered in vivo, significantly prolonged survival of NOD-SCID mice inoculated with human leukemia cells. It is noteworthy that the mice treated with antibody of the highest affinity, IMC-1121, survived the longest period of time, followed by mice treated with IMC-2C6 and IMC-1C11. Taken together, our data suggest that anti-KDR antibodies may have broad applications in the treatment of both solid tumors and leukemia. It further underscores the efforts to identify antibodies of high affinity for enhanced antiangiogenic and antitumor activities. 相似文献
999.
谷胱苷肽转移酶抑制剂高通量筛选模型的建立和初步应用 总被引:1,自引:2,他引:1
谷胱苷肽 - S-转移酶 -π( GST-π)的活性在某些类型的癌症患者中有显著的升高并且在癌症细胞对抗癌药物抗药性的形成过程中起着重要的作用。抑制过量表达的 GST-π酶的活性将有助于克服肿瘤细胞的耐药性 ,因此 ,GST-π被认为是一个潜在的药物作用的靶位点。为了筛选新的抗癌药物的增敏剂 ,我们建立了一个 GST-π酶抑制剂的高通量筛选模型 ,该模型以 CDNB和 GSH为底物 ,在 96 -孔板上通过对 340 nm处吸光度的变化来检测样品对 GST-π酶的抑制活性。经过初筛和复筛 ,从 4 80 0个微生物发酵提取物中筛选到10个阳性样品 ,阳性率为 0 .2 %。 相似文献
1000.
目的:优选复方参仲口服液的制备工艺。方法:采用L9(34)正交试验对制备工艺进行优选。结果:最佳提取工艺为8倍于生药量的水煎煮3次,每次1.0 h,醇沉浓度为70%。结论:该制备工艺合理、可行。 相似文献